

State-of-the-Art in **Benign Hematology, Hemostasis, and Thrombosis**

2025 Update on Emerging Therapeutics

October 26, 2025
Zuckerman Research Center
New York City



Memorial Sloan Kettering
Cancer Center

Overview

This one-day symposium offers a state-of-the-art update in benign hematology, with a special emphasis on emerging therapeutics.

Now in its 10th year, the 2025 program will focus on:

- Complex management scenarios in hemostasis and thrombosis, including stroke in cancer, cardiac thrombosis, and thrombotic risk in acute lymphoblastic leukemia (ALL)
- Advances in management of hemolytic anemias, with a focus on the therapeutic management of hereditary anemia, paroxysmal nocturnal hemoglobinuria (PNH), cold agglutinin disease, and other complement-mediated hemolytic disorders
- Hematologic complications related to cellular therapies and immunotherapies

The program will address complex thrombosis management scenarios—including stroke in cancer, cardiac thrombosis, and thrombotic risk in acute lymphoblastic leukemia (ALL)—as well as emerging therapies such as factor XI inhibitors and anticomplement agents, and the unique challenges associated with their use. Ample time will be provided for Q&A and discussion with the faculty.

Participant Resources

Following the symposium, registrants will receive access to an online syllabus featuring select PDF slides from faculty presentations and recorded session videos.

Target Audience

The target audience includes general medicine, hematology/oncology, fellows, hospitalists, nocturnists, emergency medicine providers, advanced practice providers and other healthcare professionals who manage and treat thrombotic and bleeding disorders.

For details and registration, visit:

msk.org/ThrombosisandHemostasis



Location

This symposium will be offered **exclusively in person** at:

Memorial Sloan Kettering Cancer Center
Zuckerman Research Center
417 East 68th Street
New York City

Educational Objectives

At the conclusion of this symposium, attendees will be able to:

- Discuss current updates in the management of challenging benign hematologic conditions, with a focus on emerging therapeutics
- Analyze current data and discuss emerging FXI inhibitors
- Describe anticomplement therapies
- Recognize the challenges in diagnosis and management of hematologic complications of immunotherapy

Credits Offered

This symposium will offer the following credit types (see **Accreditation** section for details):

- *AMA PRA Category 1 Credits™*
- ABIM Maintenance of Certification (MOC)
- ABPath Continuing Certification (CC)
- ANCC CNE Contact Hours (*pending application*)

For details and registration, visit:

msk.org/ThrombosisandHemostasis



MSK Symposium Director

Jeffrey Zwicker, MD

Chief, Hematology Service



MSK Symposium Co-Director

Rekha Parameswaran, MD

Attending Member, Hematology Service

MSK Symposium Planning Committee



Avi Leader, MD

Assistant Attending, Hematology Service



Jodi Mones, MD


Associate Program Director, Medical Oncology/Hematology Fellowship, Hematology Track;

Associate Attending, Hematology Service



Cy Wilkins, MD

Assistant Attending, Hematology Service



Natalia Tijaro Ovalle, MD

Hematology-Oncology Fellow

Symposium Faculty

Mohammad Alhomoud, MD

Assistant Attending, Marrow Transplant Service
Memorial Sloan Kettering Cancer Center

David Araten, MD

Assistant Professor of Medicine
NYU Grossman School of Medicine

Marc Carrier, MD

Professor of Medicine
University of Ottawa

Angel Chan, MD, PhD

Assistant Attending, Cardiology Service
Memorial Sloan Kettering Cancer Center

William Johnson, DO

Assistant Attending, Lymphoma Service
Memorial Sloan Kettering Cancer Center

Leslie Lake

Patient Advocate
Stop the Clot

Mohandas Narla, DSc

Distinguished Scientist
New York Blood Center Enterprises

Babak Navi, MD

Associate Professor of Neurology
Weill Cornell Medical College, Cornell University
Memorial Sloan Kettering Cancer Center

Robert Stuver, MD

Assistant Attending, Lymphoma Service
Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.



**Memorial Sloan Kettering
Cancer Center**

Schedule

Sunday, October 26, 2025 • Zuckerman Research Center

Time	Session/Faculty
8:15 AM	Breakfast & Check-in
9:00 AM	Welcome and Introduction Jeffrey Zwicker, MD


Advances in Thrombosis and Hemostasis

MODERATOR: Rekha Parameswaran, MD

9:05 AM	Emerging Data on Factor XI Inhibitors Jeffrey Zwicker, MD
9:30 AM	Cryptogenic Stroke and Cancer Babak Navi, MD
10:00 AM	Management of Right Atrial Thrombus Angel Chan, MD, PhD
10:30 AM	Break & Refreshments
11:00 AM	 Benefits of Extended Post-op Thromboprophylaxis in the Era of Robotic Surgery? Marc Carrier, MD
11:30 AM	Thrombotic Risk in Acute Lymphoblastic Leukemia Avi Leader, MD
12:00 PM	 PATIENT PERSPECTIVE Lobbying Congress to Improve Venous Thromboembolism Awareness and Funding Leslie Lake
12:30 PM	Lunch Break

Challenges of Hemolytic Conditions

MODERATOR: Jeffrey Zwicker, MD

1:30 PM	 KEYNOTE ADDRESS Inherited Hemolytic Anemias: Scientific Advances in Therapeutics Mohandas Narla, DSc
---------	--

- 2:00 PM **Management of Cold Agglutinin Disease**
Robert Stuver, MD
- 2:30 PM **Anticomplement Therapy for Paroxysmal
Nocturnal Hemoglobinuria**
David Araten, MD
- 3:00 PM **Updates in Atypical Hemolytic Uremic Syndrome**
TBA
- 3:30 PM **Break & Refreshments**

Hematologic Complications of Cellular and Immunotherapy

MODERATOR: Cy Wilkins, MD

- 4:00 PM **Hemophagocytic Lymphohistiocytosis Following
Checkpoint Inhibitors**
William Johnson, DO
- 4:30 PM **Thrombosis Related to Immune Therapy**
Jodi Mones, MD
- 5:00 PM **Transplant-Related Thrombotic Microangiopathy**
Mohammad Alhomoud, MD
- 5:30 PM **Closing Remarks and Adjournment**
Jeffrey Zwicker, MD

**Each presentation will conclude with an interactive Q&A
and discussion led by the presenting faculty.**

**Additionally, ample time will be provided during breaks
to foster networking and collaboration.**

For details and registration, visit:

msk.org/ThrombosisandHemostasis

Accreditation

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this enduring material for a maximum of **6.50 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC/CC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

- 6.50 Medical Knowledge MOC Points in the American Board of Internal Medicine's (**ABIM**) Maintenance of Certification Assessment Recognition program; and
- 6.50 Lifelong Learning (CME) credit towards the American Board of Pathology's (**ABPath**) Continuing Certification program.

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABPath MOC/CC credit.

ANCC CNE Statement

An application has been submitted for ANCC CNE contact hours.



For details and registration, visit:

msk.org/ThrombosisandHemostasis

Discounted registration is available for specific groups. If eligible, you will receive further instructions and a promotion code to use during registration.

Registration Fees

- Physicians (MDs, PhDs, and DOs): **\$300**
- Advanced Practice Providers: **\$250**
- Nursing and Other Healthcare Professionals: **\$200**
- Residents, Fellows, and Students: **\$100***
- Industry Professionals**: **\$525**
- Patients, Advocates, and Caregivers: **Complimentary**
- MSK Employees: **Complimentary**

Continental breakfast, lunch, and refreshment breaks are included with registration. If you have any special dietary needs or require specific accommodations to attend in person, please contact us at cme@mskcc.org at least one week prior to the symposium.

For details regarding our cancellation policy, please visit the symposium website: **msk.org/ThrombosisandHemostasis**

**Registration fees for residents, fellows, and students are non-refundable.*

***An “industry professional” is defined as any individual—regardless of profession (e.g., MD, PhD, APP, RN)—who is employed by an ineligible company.*



**Memorial Sloan Kettering
Cancer Center**



Memorial Sloan Kettering
Cancer Center